Literature DB >> 12187220

Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study.

Anthony J Schaeffer1, Jill S Knauss, J Richard Landis, Kathleen J Propert, Richard B Alexander, Mark S Litwin, J Curtis Nickel, Michael P O'Leary, Robert B Nadler, Michel A Pontari, Daniel A Shoskes, Scott I Zeitlin, Jackson E Fowler, Carissa A Mazurick, John W Kusek, Leroy M Nyberg.   

Abstract

PURPOSE: We examine whether leukocytes and bacteria correlate with symptom severity in men with chronic prostatitis/chronic pelvic pain syndrome.
MATERIALS AND METHODS: All 488 men screened into the National Institutes of Health Chronic Prostatitis Cohort Study before close of recruitment on August 22, 2001 were selected for analysis. The National Institutes of Health Chronic Prostatitis Symptom Index, including subscores, were used to measure symptoms. Urethral inflammation was defined as white blood cell (WBC) counts of 1 or more (1+) in the first voided urine. Participants were classified as category IIIa based on WBC counts of 5 or more, or 10 or more (5+, 10+) in the expressed prostatic secretion, or 1+ or 5+ either in the post-expressed prostatic secretion urine (voided urine 3) or semen. Uropathogens were classified as localizing if the designated bacterial species were absent in voided urine 1 and voided urine 2 but present in expressed prostatic secretion, voided urine 3 or semen, or present in expressed prostatic secretion, voided urine 3 or semen at 2 log concentrations higher than at voided urine 1 or 2. Associations between symptoms, and inflammation and infection were investigated using generalized Mantel-Haenszel methods.
RESULTS: Of all participants 50% had urethral leukocytes and of 397 with expressed prostatic secretion samples 194 (49%) and 122 (31%) had 5+ or 10+ WBCs in expressed prostatic secretion, respectively. The prevalence of category IIIa ranged from 90% to 54%, depending on the composite set of cut points. None of the index measures were statistically different (p >0.10) for selected leukocytosis subgroups. Based on prostate and semen cultures, 37 of 488 men (8%) had at least 1 localizing uropathogen. None of the index measures were statistically different (p >0.10) for selected bacterial culture subgroups.
CONCLUSIONS: Although men with chronic prostatitis routinely receive anti-inflammatory and antimicrobial therapy, we found that leukocytes and bacterial counts as we defined them do not correlate with severity of symptoms. These findings suggest that factors other than leukocytes and bacteria also contribute to symptoms associated with chronic pelvic pain syndrome.

Entities:  

Mesh:

Year:  2002        PMID: 12187220     DOI: 10.1097/01.ju.0000024762.69326.df

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  47 in total

1.  Prostate secretions from men with chronic pelvic pain syndrome inhibit proinflammatory mediators.

Authors:  Praveen Thumbikat; Shiva Shahrara; Rudina Sobkoviak; Joseph Done; Richard M Pope; Anthony J Schaeffer
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

2.  Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Choong Bum Lee; U-Syn Ha; Seung Ju Lee; Sae Woong Kim; Yong-Hyun Cho
Journal:  World J Urol       Date:  2006-01-18       Impact factor: 4.226

3.  Nutraceuticals in Prostate Disease: The Urologist's Role.

Authors:  J Curtis Nickel; Daniel Shoskes; Claus G Roehrborn; Mark Moyad
Journal:  Rev Urol       Date:  2008

4.  Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies.

Authors:  J Curtis Nickel; Richard B Alexander; Rodney Anderson; Richard Berger; Craig V Comiter; Nand S Datta; Jackson E Fowler; John N Krieger; J Richard Landis; Mark S Litwin; Mary McNaughton-Collins; Michael P O'Leary; Michel A Pontari; Anthony J Schaeffer; Daniel A Shoskes; Paige White; John Kusek; Leroy Nyberg
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

5.  Update on urologic pelvic pain syndromes: highlights from the 2010 international chronic pelvic pain symposium and workshop, august 29, 2010, kingston, ontario, Canada.

Authors:  J Curtis Nickel; Dean Tripp; Allan Gordon; Michel Pontari; Daniel Shoskes; Kenneth M Peters; Ragi Doggweiler; Andrew Paul Baranowski
Journal:  Rev Urol       Date:  2011

Review 6.  New paradigms in understanding chronic pelvic pain syndrome.

Authors:  Katy S Konkle; J Quentin Clemens
Journal:  Curr Urol Rep       Date:  2011-08       Impact factor: 3.092

Review 7.  Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment.

Authors:  Michel A Pontari
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Mechanisms in prostatitis/chronic pelvic pain syndrome.

Authors:  Michel A Pontari; Michael R Ruggieri
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

Review 9.  [Chronic prostatitis. Chronic pelvic pain syndrome].

Authors:  O Moormann; B Planz; H-P Caspers; U Wesselmann
Journal:  Schmerz       Date:  2004-04       Impact factor: 1.107

10.  Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study.

Authors:  Iona Cheng; John S Witte; Steven J Jacobsen; Reina Haque; Virginia P Quinn; Charles P Quesenberry; Bette J Caan; Stephen K Van Den Eeden
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.